At ProAct, we continue to enable affordable access to biosimilars and help ensure a smooth transition for patients starting these innovative products. Our thoughtful and comprehensive approach to include inflammatory biosimilars on our Advantage and Core formularies is projected to deliver thousands in plan cost savings by the end of 2025.
Effective March 21st, ProAct will prefer the following STELARA® (USTEKINUMAB) biosimilar products on its Advantage and Core formularies, in addition to other inflammatory products based on indication:
• SELARSDI™ (ustekinumab-aekn subcutaneous injection) by Teva
• USTEKINUMAB-TTWE (subcutaneous injection) by Quallent
• YESINTEK™ (ustekinumab-kfce subcutaneous injection) by Biocon
STELARA® will continue to be covered through 2025 on Advantage and Core formularies.
